Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) an active substance selected from umeclidinium bromide and vilanterol trifenatate and combinations thereof; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; and (d) a pharmacologically acceptable preservative, and optionally includes a pharmacologically acceptable stabilizer, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.

Abstract: The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.

Abstract: The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

Abstract: The present invention is directed to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) active substances selected from budesonide and olodaterol; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, and (e) a pharmacologically acceptable stabilizer.

Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

Abstract: The present invention relates to a pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: batefenterol or a pharmaceutically acceptable salt thereof, fluticasone furoate, and a pH adjusting agent.

Abstract: This invention relates to pharmaceutical formulations of therapeutic monoclonal antibody drugs and pharmaceutically acceptable excipients and a novel therapeutic strategy for the treatment of lung cancers including metastatic NSCLC by administration of such formulations using a soft mist inhaler and/or nebulizer. The pharmaceutical formulations comprise (a) a therapeutic monoclonal antibody selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab, (b) water, and (c) a buffer. The pharmaceutical formulations are delivered locally to the lungs by inhalation for treatment of cancer.

Abstract: The present invention relates to a liquid pharmaceutical formulation and a method for administering a pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) budesonide, olodaterol and tiotropium bromide; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) and a pharmacologically acceptable stabilizer, optionally including other pharmacologically acceptable additives.

Abstract: The present invention relates to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) an active substance selected from the group consisting of alanine metabolite, nucleoside monophosphate, nucleoside triphosphate, and GS-441524; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate and indacaterol maleate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) a pharmacologically acceptable stabilizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

Abstract: The invention provides a pharmaceutical composition for dry powder inhalation and a preparation method thereof, wherein the composition comprises, a carrier material, preferably lactose and micronized remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524 and pharmaceutically acceptable salts thereof. The active pharmaceutical ingredient may be an anti-viral, taken as remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate. and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524. The dry powder inhalation containing Remdesivir and/or its active metabolites and/or its analog GS-441524 as active ingredients, further consisting of a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation deep into the lungs for the treatment of respiratory disorders.

Abstract: The present invention relates to pharmaceutical formulations containing one or more active metabolites of remdesivir selected from alanine metabolite (Ala-met), nucleoside monophosphate, remdesivir monophosphate disodium salt and nucleoside triphosphate (NTP) or their pharmaceutically acceptable salts or solvates that are suitable for administration by soft mist inhalation or nebulization inhalation.

Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises a solvent, Tiotropium or a pharmaceutically acceptable salt thereof, Olodaterol or a pharmaceutically acceptable salt thereof, a pH adjusting agent, and a pharmacologically acceptable additive.

Abstract: The present invention relates to a liquid, propellant-free pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) the active substance tiotropium bromide; (b) a solvent; (c) a pH adjusting agent, and optionally other pharmacologically acceptable additives.

Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) Olodaterol; (b) a solvent; (c) an isoosmotic adjusting agent; (d) a pH adjusting agent, and optionally including other pharmacologically acceptable additives.

Abstract: The present invention discloses a liquid pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active levalbuterol or a salt thereof, such as levalbuterol tartrate; (b) a pharmacologically acceptable preservative; (c) a pharmacologically acceptable stabilizer, (d) a solvent, and optionally (e) other pharmacologically acceptable additives.